AETHLON MEDICAL INC

Day range

$5.01 – $5.20

Open

$5.02

Prev close

$5.05

Volume

13.83K

Market cap

$3.59M

Shares out

711.14K

P/E

—

P/S

—

P/B

0.69

P/FCF

—

ROE

-133.4%

ROA

-111.3%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Charter amendmentOct 9, 2026

  The Company's stockholders approved an amendment to the Company's Articles of Incorporation... to increase the number of authorized shares of the Company's common stock... from 20,000,000 shares to 200,000,000 shares. The Articles Amendment was filed with the Secretary of State of the State of Nevada and became effective on October 7, 2026.

• Annual meeting resultsOct 1, 2026

  On October 1, 2026 the Company held the Annual Meeting... The final voting results on the proposals presented for stockholder approval at the Annual Meeting were as follows.

• Merger agreementSep 17, 2026

  On September 17, 2026, Aethlon Medical, Inc., Nighthawk Merger Sub Corp., Nighthawk Second Merger Sub, LLC, and North Immunology, Inc. entered into an Agreement and Plan of Merger and Reorganization. First Merger Sub will merge with and into North Immunology, followed by North Immunology merging with and into Second Merger Sub.

• Executive compensation changeSep 15, 2026

  On September 11, 2026, Aethlon Medical, Inc. entered into amendments to the employment agreements of James B. Frakes, the Company's Chief Executive Officer and Chief Financial Officer, and Steven P. LaRosa, M.D., the Company's Chief Medical Officer. The Amendments provide that, if a Change in Control is consummated and, concurrently with such consummation, the applicable executive's employment is terminated under circumstances entitling the executive to severance benefits, the severance payments and applicable health care continuation payments otherwise payable in installments will instead be paid in a single lump sum.

• Warrant or conversionAug 31, 2026

  Following recent exercises of certain pre-funded warrants, Aethlon Medical, Inc. has 1,604,095 shares of common stock outstanding as of the close of business on August 28, 2026. As such, all previously outstanding pre-funded warrants have been exercised.

Days to cover

1.0

Short interest

75.45K

Avg volume

8.42M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review
  positiveBenzinga· Mar 24, 2026
• Totaligent Executes Binding LOI for Joint Venture and Acquisition of GloMed Solutions
  positiveBenzinga· Feb 25, 2026
• Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026
  neutralBenzinga· Feb 4, 2026
• Aethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAs
  positiveBenzinga· Dec 2, 2025
• Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update
  neutralBenzinga· Nov 12, 2025